Introduction: Since 2014, OnabotulinumtoxinA Botox (Allergan, Inc., Irvine, USA) represents a new therapeutic option for second-line treatment of idiopathic overactive bladder. The purpose of the current study was to evaluate practices of surgeons using onabotulinium toxin (BoNTA) in this indication.
View Article and Find Full Text PDFObjective: To examine metrologic properties of near-infrared spectroscopy (NIRS) versus transcutaneous oxygen tension (TcPO) for microcirculatory assessment of vascular transtibial stumps at the stabilized period of prosthesis fitting, as a preliminary step before exploring its ability to predict stump healing, considering the previously identified limits of TcPO (borderline area between 15 and 35mmHg).
Design: Prospective single-center observational study.
Setting: University-based rehabilitation center.